Patent intelligence · CA
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
Patent details — CA 2626142
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Sep 23, 2008
- Expiration
- Sep 18, 2028
- Applicant
- AXXONIS PHARMA AG [DE]
- CPC classes
- A61K 31/ 48 A I, A61K 47/ 10 A I, A61K 47/ 12 A I, A61K 47/ 14 A I
Quick answer
CA 2626142 (SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE) is held by AXXONIS PHARMA AG [DE]. Status: granted. Granted Sep 23, 2008. Expires Sep 18, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXXONIS PHARMA AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 48 A I, A61K 47/ 10 A I, A61K 47/ 12 A I, A61K 47/ 14 A I, A61K 47/ 18 A I, A61K 47/ 44 A I
More from AXXONIS PHARMA AG [DE]
Related pharmaceutical patents in our USPTO index.
-
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
IT MI20070164
CEROTTO TRANSDERMICO
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
DE 10341317
Mittel zur transdermalen Applikation
expired -
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
expired -
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
expired -
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
expired
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 2626142?
CA 2626142 (SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE) is held by AXXONIS PHARMA AG [DE]. Status: granted. Granted Sep 23, 2008. Expires Sep 18, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2626142?
AXXONIS PHARMA AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does CA 2626142 expire?
Our index shows an expiration date of Sep 18, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.